Beijing Leadman Biochemistry Co.,Ltd. (SHE:300289)
China · Delayed Price · Currency is CNY 7.03
+0.01 (0.14%)
At close: Feb 13, 2026
SHE:300289 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 306.74 | 336.32 | 421.98 | 675.94 | 540.94 | 449.59 |
Other Revenue | 33.91 | 33.91 | 39.57 | 30.04 | 23.12 | 21.92 |
| 340.65 | 370.23 | 461.55 | 705.98 | 564.06 | 471.51 | |
Revenue Growth (YoY) | -15.52% | -19.79% | -34.62% | 25.16% | 19.63% | -8.47% |
Cost of Revenue | 184.52 | 186.35 | 198.01 | 407.77 | 269.78 | 215.87 |
Gross Profit | 156.13 | 183.88 | 263.55 | 298.2 | 294.28 | 255.64 |
Selling, General & Admin | 159.6 | 176.94 | 183.21 | 205.67 | 179.42 | 156.78 |
Research & Development | 26.51 | 32.95 | 36.87 | 34.96 | 32.75 | 38.47 |
Other Operating Expenses | 12.02 | 10.67 | 11.79 | 12.65 | 11.07 | 6.61 |
Operating Expenses | 195.82 | 219.7 | 243.53 | 280.27 | 227.66 | 276.48 |
Operating Income | -39.69 | -35.83 | 20.02 | 17.94 | 66.62 | -20.84 |
Interest Expense | -0.21 | -0.3 | -0.65 | -1.29 | -2.15 | -2.56 |
Interest & Investment Income | 13.68 | 17.28 | 17.22 | 18.86 | 8 | 7.88 |
Currency Exchange Gain (Loss) | -0.38 | -0.38 | -0.81 | -0.75 | 1.2 | -1.12 |
Other Non Operating Income (Expenses) | -1.51 | -0.75 | -0.35 | -0.65 | -0.65 | -1.15 |
EBT Excluding Unusual Items | -28.11 | -19.98 | 35.42 | 34.11 | 73.01 | -17.79 |
Impairment of Goodwill | -71.13 | -71.13 | -14.88 | -30.53 | -20.41 | -1.81 |
Gain (Loss) on Sale of Investments | 13.65 | 14.33 | -1.85 | 1.99 | 3.47 | 8.26 |
Gain (Loss) on Sale of Assets | 1.12 | 0.01 | - | 0.45 | 1.34 | -0.93 |
Asset Writedown | -3.74 | -0.02 | -0.22 | -0.16 | -1.3 | -0.08 |
Legal Settlements | -0.06 | -0.06 | - | -32.6 | - | - |
Other Unusual Items | 4.95 | 3.67 | 6.07 | 1.57 | 2.69 | -2.44 |
Pretax Income | -83.32 | -73.18 | 24.53 | -25.16 | 58.8 | -14.79 |
Income Tax Expense | 0.67 | 1.03 | 1.87 | 10.87 | 11.62 | 14.63 |
Earnings From Continuing Operations | -83.99 | -74.21 | 22.66 | -36.03 | 47.18 | -29.42 |
Minority Interest in Earnings | 0.69 | -0.89 | -7.32 | -20.24 | -24.76 | -21.56 |
Net Income | -83.31 | -75.1 | 15.34 | -56.27 | 22.42 | -50.98 |
Net Income to Common | -83.31 | -75.1 | 15.34 | -56.27 | 22.42 | -50.98 |
Shares Outstanding (Basic) | 550 | 544 | 544 | 563 | 448 | 425 |
Shares Outstanding (Diluted) | 550 | 544 | 544 | 563 | 448 | 425 |
Shares Change (YoY) | 2.35% | -0.01% | -3.35% | 25.50% | 5.54% | 34.68% |
EPS (Basic) | -0.15 | -0.14 | 0.03 | -0.10 | 0.05 | -0.12 |
EPS (Diluted) | -0.15 | -0.14 | 0.03 | -0.10 | 0.05 | -0.12 |
Free Cash Flow | 8.23 | 33.18 | 112.11 | 69.81 | 74.56 | 107.17 |
Free Cash Flow Per Share | 0.01 | 0.06 | 0.21 | 0.12 | 0.17 | 0.25 |
Dividend Per Share | - | - | 0.010 | - | 0.020 | - |
Gross Margin | 45.83% | 49.67% | 57.10% | 42.24% | 52.17% | 54.22% |
Operating Margin | -11.65% | -9.68% | 4.34% | 2.54% | 11.81% | -4.42% |
Profit Margin | -24.45% | -20.29% | 3.32% | -7.97% | 3.98% | -10.81% |
Free Cash Flow Margin | 2.42% | 8.96% | 24.29% | 9.89% | 13.22% | 22.73% |
EBITDA | 11.4 | 18.67 | 79.05 | 76.87 | 122.16 | 31.33 |
EBITDA Margin | 3.35% | 5.04% | 17.13% | 10.89% | 21.66% | 6.64% |
D&A For EBITDA | 51.09 | 54.5 | 59.03 | 58.93 | 55.54 | 52.17 |
EBIT | -39.69 | -35.83 | 20.02 | 17.94 | 66.62 | -20.84 |
EBIT Margin | -11.65% | -9.68% | 4.34% | 2.54% | 11.81% | -4.42% |
Effective Tax Rate | - | - | 7.63% | - | 19.76% | - |
Revenue as Reported | 340.65 | 370.23 | 461.55 | 705.98 | 564.06 | 471.51 |
Advertising Expenses | - | 1.01 | 2.14 | 2.82 | 2.27 | 2.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.